• Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
  • Log In
    • Register
Contacts us @ MediPr.org
Medical News Asia | Powered by ['mediPr]
  • MDnews
  • About [‘mediPr]
  • Search
  • Menu Menu

Non-Sponsored Content


TARGETED THERAPY

Lower-risk MDS patients benefit from novel drug, imetelstat

Medical writer: Kirsty LEE | Last updated: 10 July 2020 | In: Haematology, Oncology

Article Keywords

human telomerase reverse transcriptase, imetelstat, MDS, myelodysplastic syndromes, AML, red blood cell transfusion, anaemia, EPO, erythropoietin stimulating agents, ESA, haematopoietic disorders, hTERT

Myelodysplastic syndromes (MDS) are a heterogenous group of clonal haematopoietic disorders that carry a risk of progression to acute myeloid leukaemia (AML).1Bewersdorf JP, Zeidan AM. Ann Hematol. 2020 Apr;99(4):677-692. Patients are stratified into risk groups due to the heterogeneity of the disease, which is also exemplified by median overall survival (OS) of 8.8 years for very low risk, and 0.8 years for very high risk patients.1Bewersdorf JP, Zeidan AM. Ann Hematol. 2020 Apr;99(4):677-692. Due to symptoms such as anaemia, supportive red blood cell (RBC) transfusions are needed in 80-90% of patients during their disease course and RBC dependence is shown to be an adverse prognostic marker.1Bewersdorf JP, Zeidan AM. Ann Hematol. 2020 Apr;99(4):677-692.

Imetelstat, a novel telomerase inhibitor, has emerged as a new treatment option for lower-risk (LR) MDS patients.1Bewersdorf JP, Zeidan AM. Ann Hematol. 2020 Apr;99(4):677-692. Telomere shortening and dysregulation of telomerase activity have been associated with inferior survival in MDS.1Bewersdorf JP, Zeidan AM. Ann Hematol. 2020 Apr;99(4):677-692. Imetelstat is currently being investigated in IMerge, a phase 2/3 global study, for transfusion-dependent patients with LR MDS and relapsed or refractory to erythropoietin stimulating agents (ESA R/R).2Platzbecker U. Abstract S183. Presented at the European Hematology Association 2020 (June 11-21). Available at: https://ww3.mdne.ws/3fGlVXS (Accessed 7 July 2020). The long-term efficacy and safety results of this trial were reported at the European Hematology Association 25th Annual Congress in 2020.

Patients received imetelstat 7.5mg/kg IV Q4W, and 38 LR non-del(5q) transfusion-dependent ESA R/R MDS patients were followed for a median of 24 months.2Platzbecker U. Abstract S183. Presented at the European Hematology Association 2020 (June 11-21). Available at: https://ww3.mdne.ws/3fGlVXS (Accessed 7 July 2020). Long-term efficacy outcomes included ≥8-week, ≥24-week, and ≥1-year RBC transfusion-independence (TI) rates, longest and cumulative duration of ≥8-week TI, duration of haematologic improvement-erythroid, and major/minor response according to updated International Working Group (IWG) 2018 guidelines.2Platzbecker U. Abstract S183. Presented at the European Hematology Association 2020 (June 11-21). Available at: https://ww3.mdne.ws/3fGlVXS (Accessed 7 July 2020). All 38 patients had a high transfusion burden (≥4 units per 8 weeks), and 84% had a burden of ≥6 units per 8 weeks.2Platzbecker U. Abstract S183. Presented at the European Hematology Association 2020 (June 11-21). Available at: https://ww3.mdne.ws/3fGlVXS (Accessed 7 July 2020). Of all participants, 89% had received prior ESAs, and 32% had EPO levels exceeding 500U/L.2Platzbecker U. Abstract S183. Presented at the European Hematology Association 2020 (June 11-21). Available at: https://ww3.mdne.ws/3fGlVXS (Accessed 7 July 2020).

In these 38 patients, 42% had ≥8-week TI, 32% achieved ≥24-week TI, and 29% with a median transfusion burden of 6 units per 8 weeks were transfusion-free for over 1-year.2Platzbecker U. Abstract S183. Presented at the European Hematology Association 2020 (June 11-21). Available at: https://ww3.mdne.ws/3fGlVXS (Accessed 7 July 2020). Clinically meaningful major and minor responses (16-week TI and 50% transfusion reduction/16 weeks) were achieved by 37% and 55% of patients, per IWG guidelines.2Platzbecker U. Abstract S183. Presented at the European Hematology Association 2020 (June 11-21). Available at: https://ww3.mdne.ws/3fGlVXS (Accessed 7 July 2020). The 42% 8-week TI rate is the longest reported with any agent in non-del(5q) LR-MDS patients. Grade ≥3 cytopenias were the most frequently reported adverse events but were manageable and reversible.2Platzbecker U. Abstract S183. Presented at the European Hematology Association 2020 (June 11-21). Available at: https://ww3.mdne.ws/3fGlVXS (Accessed 7 July 2020).

Over 50% reduction of telomerase activity and human telomerase reverse transcriptase (hTERT) RNA levels post-imetelstat dosing were used to demonstrate on-target imetelstat activity, which was observed in 23.1% and 54.3% of patients, respectively.2Platzbecker U. Abstract S183. Presented at the European Hematology Association 2020 (June 11-21). Available at: https://ww3.mdne.ws/3fGlVXS (Accessed 7 July 2020). A significantly higher proportion of patients had ≥50% hTERT expression reduction when achieving ≥8-week TI compared with patients without TI (80% vs. 35%; p=0.0155).2Platzbecker U. Abstract S183. Presented at the European Hematology Association 2020 (June 11-21). Available at: https://ww3.mdne.ws/3fGlVXS (Accessed 7 July 2020). This was also seen in patients achieving ≥24-week TI vs. patients without TI (91.7% vs. 34.8%; p=0.0016). This indicates there may be a correlation between telomerase inhibition and clinical benefit.2Platzbecker U. Abstract S183. Presented at the European Hematology Association 2020 (June 11-21). Available at: https://ww3.mdne.ws/3fGlVXS (Accessed 7 July 2020).

Reference

  1. Bewersdorf JP, Zeidan AM. Ann Hematol. 2020 Apr;99(4):677-692.
  2. Platzbecker U. Abstract S183. Presented at the European Hematology Association 2020 (June 11-21). Available at: https://ww3.mdne.ws/3fGlVXS (Accessed 7 July 2020)


YOU MAY ALSO LIKE

Dosing issues with DOACs in Asian real world setting

Dosing issues with DOACs in Asian real world setting

/wp-content/uploads/2021/12/Dosing-issues-with-DOACs-in-Asian-real-world-setting-e1645234196630.jpg 1024 1917 Connie TANG https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Connie TANG2021-12-23 18:58:462022-02-20 04:03:16Dosing issues with DOACs in Asian real world setting
The-evolution-of-hypertension-management

The evolution of hypertension management

/wp-content/uploads/2021/08/The-evolution-of-hypertension-management.jpg 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-08-20 16:34:052022-02-20 10:31:52The evolution of hypertension management
COVID-19-impacting-regular-patient-care-for-cardiovascular-diseases

COVID-19 impacting regular patient care for cardiovascular diseases

/wp-content/uploads/2021/02/COVID-19-impacting-regular-patient-care-for-cardiovascular-diseases.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-17 11:52:282022-05-17 05:46:03COVID-19 impacting regular patient care for cardiovascular diseases
SARS-CoV-2-infection-in-children-and-an-increased-risk-of-thrombotic-microangiopathy

SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

/wp-content/uploads/2021/02/SARS-CoV-2-infection-in-children-and-an-increased-risk-of-thrombotic-microangiopathy.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-10 15:41:562022-05-17 05:46:03SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy
PreviousNext
Dosing issues with DOACs in Asian real world setting
23 December 2021

Dosing issues with DOACs in Asian real world setting

The-evolution-of-hypertension-management
20 August 2021

The evolution of hypertension management

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

© Copyright 2020 MediPaper Medical Communications Ltd. – Lower-risk MDS patients benefit from novel drug, imetelstat

YOU MAY ALSO LIKE

Dosing issues with DOACs in Asian real world setting

Dosing issues with DOACs in Asian real world setting

/wp-content/uploads/2021/12/Dosing-issues-with-DOACs-in-Asian-real-world-setting-e1645234196630.jpg 1024 1917 Connie TANG https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Connie TANG2021-12-23 18:58:462022-02-20 04:03:16Dosing issues with DOACs in Asian real world setting
The-evolution-of-hypertension-management

The evolution of hypertension management

/wp-content/uploads/2021/08/The-evolution-of-hypertension-management.jpg 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-08-20 16:34:052022-02-20 10:31:52The evolution of hypertension management
COVID-19-impacting-regular-patient-care-for-cardiovascular-diseases

COVID-19 impacting regular patient care for cardiovascular diseases

/wp-content/uploads/2021/02/COVID-19-impacting-regular-patient-care-for-cardiovascular-diseases.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-17 11:52:282022-05-17 05:46:03COVID-19 impacting regular patient care for cardiovascular diseases
SARS-CoV-2-infection-in-children-and-an-increased-risk-of-thrombotic-microangiopathy

SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

/wp-content/uploads/2021/02/SARS-CoV-2-infection-in-children-and-an-increased-risk-of-thrombotic-microangiopathy.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-10 15:41:562022-05-17 05:46:03SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy
Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates

Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates

/wp-content/uploads/2021/02/Registry-data-shows-early-and-large-LDL-reductions-are-associated-with-lowest-post-MI-cardiovascular-event-rates.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-10 10:35:042022-02-20 03:45:02Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates
data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia

Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia

/wp-content/uploads/2020/10/data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 16:12:402022-05-17 05:46:04Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia
psoriasis-biologics-may-help-reduce-coronary-plaque

Psoriasis biologics may help reduce coronary plaque

/wp-content/uploads/2020/10/psoriasis-biologics-may-help-reduce-coronary-plaque.webp 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 15:45:112022-05-17 05:46:04Psoriasis biologics may help reduce coronary plaque
ticagrelor-may-not-confer-post-mi-benefits-to-elderly-patients

Ticagrelor may not confer post-MI benefits to elderly patients

/wp-content/uploads/2020/10/ticagrelor-may-not-confer-post-mi-benefits-to-elderly-patients.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 15:05:532022-05-17 05:46:04Ticagrelor may not confer post-MI benefits to elderly patients
Evidence-of-SARS-CoV2-in-heart-cells

Evidence of SARS-CoV2 in heart cells

/wp-content/uploads/2020/09/Evidence-of-SARS-CoV2-in-heart-cells.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-22 10:19:272022-05-17 05:46:04Evidence of SARS-CoV2 in heart cells
risk-of-thrombosis-with-sars-cov-2-infection

Risk of thrombosis with SARS-CoV-2 infection

/wp-content/uploads/2020/08/risk-of-thrombosis-with-sars-cov-2-infection.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-27 16:33:072022-05-17 05:46:04Risk of thrombosis with SARS-CoV-2 infection
further-analyses-of-dapa-hf-shows-dapagliflozin-leads-to-fewer-outpatient-heart-failure

Class effect of SGLT2 inhibitors on heart failure reduction solidified with dapagliflozin and empagliflozin results

/wp-content/uploads/2020/08/further-analyses-of-dapa-hf-shows-dapagliflozin-leads-to-fewer-outpatient-heart-failure.jpg 1024 1818 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-25 14:40:232022-02-24 03:54:01Class effect of SGLT2 inhibitors on heart failure reduction solidified with dapagliflozin and empagliflozin results
potential-protective-effects-of-the-influenza-vaccine-on-cardiovascular-outcomes-in-high-risk-populations

Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations

/wp-content/uploads/2020/08/potential-protective-effects-of-the-influenza-vaccine-on-cardiovascular-outcomes-in-high-risk-populations.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-13 15:28:132022-02-24 03:59:44Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations
Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection

Highlights of the 8th Asia Pacific Symposium on Cerebrovascular Disease

/wp-content/uploads/2019/12/Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-12-16 10:35:082022-02-24 09:16:12Highlights of the 8th Asia Pacific Symposium on Cerebrovascular Disease
Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection

I-O in Special Populations: Chronic Viral Hepatitis Carriers

0 0 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-11-18 21:51:462018-11-18 21:51:46I-O in Special Populations: Chronic Viral Hepatitis Carriers
Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection

Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study

0 0 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-28 15:23:462018-09-28 15:23:46Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study
Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection

Transcatheter- vs surgical aortic valve replacement in high-risk patients: 5-years survival

0 0 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-28 12:43:062018-09-28 12:43:06Transcatheter- vs surgical aortic valve replacement in high-risk patients: 5-years survival
Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection

Anti-coagulation: impact on long-term mortality and early valve dysfunction

0 0 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-19 10:30:462018-09-19 10:30:46Anti-coagulation: impact on long-term mortality and early valve dysfunction
Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection

Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety

0 0 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-29 23:13:062018-08-29 23:13:06Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety
Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection

Febuxostat prevents CV events in hyperuricaemia patients

0 0 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-29 11:32:012018-08-29 11:32:01Febuxostat prevents CV events in hyperuricaemia patients
Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection

Standard- and low-dose rivaroxaban in Asians with AF: Effectiveness and Safety

0 0 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-30 09:51:512018-07-30 09:51:51Standard- and low-dose rivaroxaban in Asians with AF: Effectiveness and Safety
Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection

ASCO16 Nivolumab (Opdivo©) Data

0 0 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-29 00:44:422016-05-29 00:44:42ASCO16 Nivolumab (Opdivo©) Data
PreviousNext
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

© Copyright 2020 MediPaper Medical Communications Ltd. – Lower-risk MDS patients benefit from novel drug, imetelstat

Categories

Newsletter


 MediPR | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | Medical Writer Jobs | PMHub
© 2016-2022 MediPaper Medical Communications Ltd. | Website by [’mediPr] | 醫學作家香港 | Privacy Policy | Cookie Policy
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
Carboplatin plus paclitaxel to be the new standard of care for anal cancerCarboplatin-plus-paclitaxel-to-be-the-new-standard-of-care-for-anal-cancercomparison-of-the-metabolic-changes-from-the-tango-trial-a-post-hoc-analysisComparison of the metabolic changes from the TANGO trial: a post-hoc analys...
Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings×

Cookies and Privacy on medi-paper.com



Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

5
Accept settingsHide notification only
  • LinkedIn
  • WhatsApp
  • Facebook
  • Twitter
  • Pinterest
  • More Networks
Share via
Facebook
Twitter
LinkedIn
Mix
Pinterest
Tumblr
Skype
Buffer
Pocket
VKontakte
Parler
Xing
Reddit
Flipboard
MySpace
Delicious
Amazon
Digg
Evernote
Blogger
LiveJournal
Baidu
MeWe
NewsVine
Yummly
Yahoo
WhatsApp
Viber
SMS
Telegram
Facebook Messenger
Like
Email
Print
Copy Link
Copy link
CopyCopied